1
|
Thornalley PJ and Dodd NJ: Free radical
production from normal and adriamycin-treated rat cardiac
sarcosomes. Biochem Pharmacol. 34:669–674. 1985. View Article : Google Scholar : PubMed/NCBI
|
2
|
Pommier Y: DNA topoisomerase I and II in
cancer chemotherapy: update and perspectives. Cancer Chemother
Pharmacol. 32:103–108. 1993. View Article : Google Scholar : PubMed/NCBI
|
3
|
Weinstein-Oppenheimer CR, Henríquez-Roldán
CF, Davis JM, et al: Role of the Raf signal transduction cascade in
the in vitro resistance to the anticancer drug doxorubicin. Clin
Cancer Res. 7:2898–2907. 2001.PubMed/NCBI
|
4
|
Kim SH, Lee SH, Kwak NH, Kang CD and Chung
BS: Effects of the activated Raf protein kinase on the human
multidrug resistance 1 (MDR1) gene promoter. Cancer Lett.
98:199–205. 1996. View Article : Google Scholar : PubMed/NCBI
|
5
|
Cornwell MM and Smith DE: A signal
transduction pathway for activation of the mdr1 promoter involves
the proto-oncogene c-raf kinase. J Biol Chem. 268:15347–15350.
1993.PubMed/NCBI
|
6
|
Mas VM, Hernandez H, Plo I, et al: Protein
kinase Czeta mediated Raf-1/extracellular-regulated kinase
activation by daunorubicin. Blood. 101:1543–1550. 2003. View Article : Google Scholar : PubMed/NCBI
|
7
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
8
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Kornblau SM, Womble M, Qiu YH, et al:
Simultaneous activation of multiple signal transduction pathways
confers poor prognosis in acute myelogenous leukemia. Blood.
108:2358–2365. 2006. View Article : Google Scholar : PubMed/NCBI
|
10
|
Kolch W: Coordinating ERK/MAPK signalling
through scaffolds and inhibitors. Nat Rev Mol Cell Biol. 6:827–837.
2005. View
Article : Google Scholar : PubMed/NCBI
|
11
|
Yoon S and Seger R: The extracellular
signal-regulated kinase: multiple substrates regulate diverse
cellular functions. Growth Factors. 24:21–44. 2006. View Article : Google Scholar : PubMed/NCBI
|
12
|
McCubrey JA, Steelman LS, Chappell WH, et
al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant
transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
13
|
Giehl K: Oncogenic Ras in tumour
progression and metastasis. Biol Chem. 386:193–205. 2005.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Thompson N and Lyons J: Recent progress in
targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug
discovery. Curr Opin Pharmacol. 5:350–356. 2005. View Article : Google Scholar : PubMed/NCBI
|
15
|
Escudier B, Eisen T, Stadler WM, et al:
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J
Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
16
|
Strumberg D, Clark JW, Awada A, et al:
Safety, pharmaco-kinetics, and preliminary antitumor activity of
sorafenib: a review of four phase I trials in patients with
advanced refractory solid tumors. Oncologist. 12:426–437. 2007.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Wilhelm SM, Carter C, Tang L, et al: BAY
43-9006 exhibits broad spectrum oral antitumor activity and targets
the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in
tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Wilhelm S, Carter C, Lynch M, et al:
Discovery and development of sorafenib: a multikinase inhibitor for
treating cancer. Nat Rev Drug Discov. 5:835–844. 2006. View Article : Google Scholar : PubMed/NCBI
|
19
|
Cummings J, Anderson L, Willmott N and
Smyth JF: The molecular pharmacology of doxorubicin in vivo. Eur J
Cancer. 27:532–535. 1991. View Article : Google Scholar : PubMed/NCBI
|
20
|
Quillet-Mary A, Mansat V, Duchayne E, et
al: Daunorubicin-induced internucleosomal DNA fragmentation in
acute myeloid cell lines. Leukemia. 10:417–425. 1996.PubMed/NCBI
|
21
|
Hannun YA: Functions of ceramide in
coordinating cellular responses to stress. Science. 274:1855–1861.
1996. View Article : Google Scholar : PubMed/NCBI
|
22
|
Han W, Sun J, Feng L, et al: Autophagy
inhibition enhances daunorubicin-induced apoptosis in K562 cells.
PLoS One. 6:e284912011. View Article : Google Scholar : PubMed/NCBI
|
23
|
Weinstein-Oppenheimer CR, Blalock BL,
Steelman LS, et al: The Raf signal transduction cascade as a target
for chemotherapeutic intervention in growth factor responsive
tumors. Pharmacol Ther. 88:229–279. 2000. View Article : Google Scholar : PubMed/NCBI
|
24
|
Abrams SL, Steelman LS, Shelton JG, et al:
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and
sensitivity to targeted therapy. Cell Cycle. 9:1781–1791. 2010.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Dasmahapatra G, Yerram N, Dai Y, Dent P
and Grant S: Synergistic interactions between vorinostat and
sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and
p21CIP1 down-regulation. Clin Cancer Res. 13:4280–4290. 2007.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Yu C, Friday BB, Lai JP, et al: Cytotoxic
synergy between the multikinase inhibitor sorafenib and the
proteasome inhibitor bortezomib in vitro: induction of apoptosis
through Akt and c-Jun NH2-terminal kinase pathways. Mol
Cancer Ther. 5:2378–2387. 2006. View Article : Google Scholar : PubMed/NCBI
|
27
|
Towatari M, Iida H, Tanimoto M, et al:
Constitutive activation of mitogen-activated protein kinase pathway
in acute leukemia cells. Leukemia. 11:479–484. 1997. View Article : Google Scholar : PubMed/NCBI
|
28
|
Laurent G and Jaffrézou JP: Signaling
pathways activated by daunorubicin. Blood. 98:913–924. 2001.
View Article : Google Scholar : PubMed/NCBI
|